Product Description
Mechanisms of Action: D2 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous,Transdermal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | Colombia | Dominican Republic | Egypt | France | Germany | Ireland | Italy | Mexico | New Zealand | Pakistan | Peru | Portugal | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Axxonis Pharma AG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Parkinson's Disease|Restless Legs Syndrome|Psychomotor Agitation
Phase 2: Parkinson's Disease|Hypertension, Pulmonary
Phase 1: Cocaine-Related Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Lis-Safe | P2 |
Terminated |
Hypertension, Pulmonary |
2014-08-19 |
|
CALIPSO | P3 |
Completed |
Parkinson's Disease |
2009-10-02 |
|
TULEP 1 | P3 |
Active, not recruiting |
Parkinson's Disease |
2008-09-20 |
|
Tulir03/01 | P3 |
Active, not recruiting |
Restless Legs Syndrome |
2007-09-08 |